Ariad Reaches New 52-Week High (ARIA)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Ariad Pharmaceuticals (Nasdaq: ARIA) hit a new 52-week high Tuesday as it is currently trading at $24.05, above its previous 52-week high of $24.03 with 673,826 shares traded as of 10:46 a.m. ET. Average volume has been two million shares over the past 30 days.

Ariad has a market cap of $3.92 billion and is part of the health care sector and drugs industry. Shares are up 92.7% year to date as of the close of trading on Monday.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates Ariad as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and feeble growth in the company's earnings per share. You can view the full Ariad Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)